List of Excipients in Branded Drug TINIDAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BioComp Pharma Inc	TINIDAZOLE	tinidazole	44523-450	ALUMINUM OXIDE
BioComp Pharma Inc	TINIDAZOLE	tinidazole	44523-450	CELLULOSE, MICROCRYSTALLINE
BioComp Pharma Inc	TINIDAZOLE	tinidazole	44523-450	CROSCARMELLOSE SODIUM

Generic Drugs Containing TINIDAZOLE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	tinidazole	0054-0347	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	tinidazole	0054-0347	COPOVIDONE K25-31
Hikma Pharmaceuticals USA Inc	tinidazole	0054-0347	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in TINIDAZOLE?

# Of NDCs	Excipient
8	CELLULOSE, MICROCRYSTALLINE
2	COPOVIDONE K25-31
8	CROSCARMELLOSE SODIUM

Tinidazole Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Tinidazole is an established, off-patent nitroimidazole with limited active-ingredient exclusivity but meaningful formulation opportunities. The strongest commercial positions are pediatric taste-masked products, ready-to-use oral suspensions, unit-dose sachets, orally disintegrating tablets, and differentiated combination products. The U.S. market is primarily generic and immediate-release, so success depends on dosage-form convenience, palatability, supply reliability, and regulatory execution rather than new-molecule patent protection.

What is the regulatory and commercial status of tinidazole?

Tinidazole is an FDA-approved oral antimicrobial used for trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis. The U.S. reference product is Tindamax, marketed by Mission Pharmacal in 250 mg and 500 mg tablets. The product is administered orally, generally as a single dose or short course depending on the indication (FDA, 2023a).

Attribute	Tinidazole
Active ingredient	Tinidazole
Pharmacologic class	Nitroimidazole antimicrobial
U.S. reference product	Tindamax
U.S. dosage forms	Immediate-release tablets
Common strengths	250 mg and 500 mg
FDA route	Oral
Primary indications	Trichomoniasis, giardiasis, amebiasis, bacterial vaginosis
Regulatory market	Generic and multisource
Biologic status	Not applicable
Biosimilar pathway	Not applicable
Principal commercial issue	Differentiated delivery and palatability

Tinidazole has advantages over some competing nitroimidazoles because several indications use short or single-dose regimens. That creates a commercial rationale for products that improve administration, reduce dosing errors, and increase adherence.

When does tinidazole lose exclusivity?

Tinidazole has no meaningful remaining U.S. active-ingredient exclusivity. The compound and conventional oral tablet technology are mature, and generic tinidazole products are available.

The relevant U.S. regulatory pathway for a conventional generic tablet is generally an Abbreviated New Drug Application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. A conventional product must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product. A novel dosage form, new route, or materially different formulation may require a 505(b)(2) application instead.

The main commercial implication is that a new tinidazole tablet would face direct generic competition. A formulation sponsor would need a defensible point of difference, such as:

• pediatric suitability;
• improved taste;
• reduced tablet burden;
• a stable liquid presentation;
• rapid disintegration;
• unit-dose packaging;
• improved supply reliability;
• a new combination product;
• a non-oral delivery system.

What patents protect tinidazole products?

No high-value U.S. composition-of-matter patent protects tinidazole. Conventional tinidazole tablets are generally exposed to generic competition.

The FDA Orange Book remains the primary source for checking listed patents, exclusivity, therapeutic-equivalence codes, and approved applications. Patent status should be reviewed by product, applicant, strength, and dosage form because an absence of protection for tablets does not eliminate possible protection for a later-developed suspension, combination, or delivery system (FDA, 2024).

IP category	Tinidazole commercial relevance
Composition-of-matter patents	No meaningful current protection expected
Conventional tablet patents	Low barrier; mature technology
Formulation patents	Potentially available for novel suspension, taste masking, rapid disintegration, or controlled release
Method-of-use patents	Limited value where indications are established and labeling is generic
Combination-product patents	Possible opportunity if the combination has a distinct clinical or regulatory rationale
Manufacturing patents	Potential protection for particle engineering, impurity control, or continuous processing
Regulatory exclusivity	No significant current U.S. exclusivity expected

Patentability is more plausible for a specific excipient system or manufacturing process than for the use of tinidazole itself. Claims must be drafted around measurable technical features, such as dissolution, stability, sedimentation, redispersibility, taste scores, impurity limits, or bioequivalence performance.

What excipients are used in tinidazole tablets?

Tinidazole immediate-release tablets typically use a conventional solid-dose excipient platform. Public product labeling identifies inactive ingredients for marketed products, although the exact composition varies by manufacturer and strength.

Relevant excipient functions include:

Excipient function	Candidate materials	Formulation purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, mannitol	Tablet mass and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Rapid breakup after ingestion
Lubricant	Magnesium stearate, sodium stearyl fumarate	Manufacturing release and reduced sticking
Glidant	Colloidal silicon dioxide	Powder flow
Film former	Hypromellose, polyvinyl alcohol	Appearance, handling, and swallowability
Opacifier or colorant	Titanium dioxide or approved colorants	Product identification and light protection
Sweetener or flavor	Sucralose, saccharin sodium, flavors	Palatability in chewable or liquid products

The key technical constraint is dose size. Tinidazole tablets can contain a substantial active load, particularly at 500 mg. A high-load formulation leaves less room for taste-masking polymers, superdisintegrants, coating weight, or specialized excipients. Direct compression may offer a shorter process, but wet granulation can improve blend uniformity, compressibility, and content uniformity when particle-size or flow characteristics are unfavorable.

What excipient strategy is best for a tinidazole pediatric product?

Pediatric formulation is the clearest excipient-led opportunity. Tinidazole is used in pediatric patients for certain protozoal infections, but tablets can be difficult for young children to swallow. The active ingredient also has a strong bitter taste, making a liquid or dispersible formulation commercially relevant.

A pediatric strategy should use a layered approach:

1. Reduce dissolution of tinidazole in the mouth.
2. Prevent immediate exposure of dissolved drug to taste receptors.
3. Promote rapid release after swallowing.
4. Maintain chemical and microbiological stability.
5. Support accurate dose measurement.

Suitable platforms include:

• coated granules for reconstitution;
• taste-masked dry suspensions;
• orally disintegrating tablets;
• mini-tablets;
• chewable tablets;
• dispersible tablets;
• unit-dose powder sachets.

Taste masking

Taste masking is likely to be the primary technical challenge. Candidate approaches include polymer coating, lipid coating, ion-complex formation, and multiparticulate encapsulation. Coating materials may include ethylcellulose, methacrylate copolymers, hypromellose, or lipid excipients, subject to dissolution and regulatory acceptability.

A successful system must prevent release in the oral cavity without delaying gastrointestinal release. Excessive coating can reduce dissolution, create bioequivalence risk, or produce variable release after reconstitution.

For a suspension, sweeteners and flavors alone may not adequately mask tinidazole. A physical barrier around the drug particle is more defensible than flavor optimization alone. The formulation should be evaluated with a validated human taste panel or an appropriate in-vitro taste-screening system, together with dissolution testing under clinically relevant conditions.

Suspending and wetting systems

A reconstituted suspension may require:

• a suspending polymer such as xanthan gum, hydroxypropyl methylcellulose, or sodium carboxymethylcellulose;
• a wetting agent such as polysorbate 80 or a permitted alternative;
• a buffer system;
• a preservative where the product is multidose;
• a sweetener and flavor;
• a chelating agent or antioxidant if required by stability data.

The formulation must balance viscosity and dose uniformity. Excessive viscosity reduces pourability and makes administration difficult. Poor wetting produces floating or clumped particles and causes dose variability.

A dry powder for reconstitution has a commercial advantage over a ready-to-use liquid because it reduces shipping weight and may improve shelf stability. The tradeoff is the need for clear reconstitution instructions, a suitable measuring device, and defined in-use stability after water is added.

What formulations are protected by tinidazole excipient patents?

Novel formulation claims may protect:

• a specific taste-masked tinidazole particle;
• a dry suspension with defined particle-size distribution;
• a reconstituted product with a specified sedimentation profile;
• an orally disintegrating tablet with a defined disintegration time;
• a dispersible tablet with rapid dissolution;
• a low-impurity manufacturing process;
• a stabilized aqueous formulation;
• a unit-dose combination with another antimicrobial or antiparasitic.

A commercially useful patent should connect the excipient system to a measurable benefit. Broad claims covering “tinidazole with a pharmaceutically acceptable excipient” are unlikely to provide a strong barrier because conventional excipient combinations are predictable and widely used.

The strongest formulation claims would typically include quantitative limitations, such as:

• drug loading;
• polymer-to-drug ratio;
• coating weight gain;
• particle-size range;
• reconstitution time;
• sedimentation volume;
• redispersibility cycles;
• dissolution at defined time points;
• residual solvent;
• impurity level;
• stability under defined temperature and humidity conditions.

What FDA pathway applies to a new tinidazole formulation?

A conventional immediate-release tablet that matches the reference product may qualify for a 505(j) generic application. A materially different formulation may require a 505(b)(2) application, particularly when the sponsor relies on published literature or FDA findings for the active ingredient while introducing a new dosage form, route, or formulation.

Product concept	Likely U.S. pathway
Conventional 250 mg or 500 mg tablet	505(j)
Bioequivalent film-coated tablet	505(j)
Taste-masked pediatric granules	Potentially 505(b)(2), depending on reference and reliance strategy
Ready-to-use oral suspension	Potentially 505(b)(2)
Dry powder for reconstitution	Potentially 505(b)(2) or generic pathway if a suitable reference exists
Orally disintegrating tablet	Depends on reference product and formulation differences
Intravaginal or topical product	Likely 505(b)(2) or another product-specific pathway
Combination product	Product-specific combination regulatory strategy

FDA review would focus on pharmaceutical quality, bioequivalence or comparative bioavailability, impurities, microbial control, preservative effectiveness, container closure, and stability. For a pediatric liquid, FDA would also scrutinize dose uniformity throughout the bottle, reconstitution instructions, in-use stability, and measuring-device accuracy.

What generic entry risks exist for tinidazole?

Generic entry risk is high for standard tablets and lower for differentiated products with technical barriers.

Product type	Generic entry risk	Main barrier
Standard immediate-release tablet	High	Low formulation complexity
Film-coated tablet	High	Limited technical differentiation
Chewable tablet	Medium	Taste and mechanical performance
Orally disintegrating tablet	Medium	Taste masking and rapid release
Dry suspension	Medium	Reconstitution and dose uniformity
Ready-to-use suspension	Medium to low	Stability, preservation, packaging
Controlled-release product	Medium	Clinical and bioequivalence complexity
Novel combination	Variable	Clinical rationale and regulatory requirements

A pediatric suspension can delay direct substitution if it has no therapeutically equivalent generic listed in the same dosage form. That advantage is regulatory and commercial, not necessarily permanent. Once a market is established, competitors can develop comparable products.

Which companies are challenging tinidazole exclusivity?

Tinidazole is a mature generic product, so competition is expected from multiple generic manufacturers rather than from a concentrated Paragraph IV campaign. The relevant competitive set can include manufacturers marketing tinidazole tablets, contract development organizations offering taste-masking or suspension platforms, and branded-generic companies selling anti-infective products in emerging markets.

Paragraph IV litigation is most relevant when a new applicant challenges a listed patent. Because conventional tinidazole tablet protection is limited, the principal litigation risk for a new formulation would arise from formulation, combination, or process patents rather than from the active ingredient.

A sponsor pursuing a novel tinidazole product should expect freedom-to-operate review across:

• U.S. formulation patents;
• foreign suspension and taste-masking patents;
• excipient supplier licenses;
• coating-process technology;
• container-closure technology;
• third-party combination patents;
• trademark and trade-dress rights.

What licensing deals could support tinidazole commercialization?

Licensing opportunities are more likely to involve formulation technology than the tinidazole molecule. Potential deal structures include:

• regional licensing of a pediatric suspension;
• exclusive rights to a taste-masking platform;
• supply agreements for coated tinidazole particles;
• contract manufacturing of dry powder for reconstitution;
• co-development with a generic manufacturer;
• distribution rights in countries where pediatric anti-infective access is limited.

The most valuable license would provide regulatory-ready formulation data, scalable manufacturing, and enforceable IP. A simple license to use a common excipient combination would have limited strategic value.

How does tinidazole compare with metronidazole?

Tinidazole competes mainly with metronidazole and, in some indications, other antiparasitic or antimicrobial products.

Commercial factor	Tinidazole	Metronidazole
Dosing convenience	Often favorable, including single-dose regimens	Frequently requires multiple doses
Market maturity	Generic	Generic
Formulation opportunity	Pediatric suspension, dispersible and taste-masked forms	Broad competition across tablets, liquids, topical and vaginal products
Taste challenge	Significant	Significant
Brand differentiation	Limited in U.S.	More established across dosage forms
Manufacturing complexity	Low for tablets; higher for novel liquids	Low to high depending on dosage form
Patent opportunity	Mainly formulation and process	Mainly formulation, delivery, and combination products

Tinidazole may support a premium over commodity tablets if a product reduces dosing frequency or solves administration problems. A premium is less defensible where the product has the same tablet presentation and no measurable patient benefit.

What geographic markets offer commercial opportunities?

The strongest geographic opportunities are markets with:

• high rates of protozoal infection;
• limited access to pediatric dosage forms;
• fragmented generic supply;
• weak availability of palatable oral liquids;
• established pharmacy distribution;
• regulatory pathways for generic or hybrid products.

Emerging markets may favor low-cost dry suspensions, sachets, or dispersible tablets. Higher-income markets may support premium pediatric products if the product has validated palatability, convenient dosing, and reliable reimbursement.

Global launch planning must account for different excipient requirements, permitted colorants, preservative standards, labeling rules, and stability zones. A formulation designed for one regulatory region may require changes for hot and humid climates, especially where the product is packaged in multidose bottles.

How strong is the tinidazole patent estate?

The patent estate for conventional tinidazole products is weak. The commercial estate can become stronger if built around a proprietary formulation with:

• a clear clinical or administration benefit;
• difficult-to-reproduce particle engineering;
• validated taste masking;
• robust stability;
• a scalable manufacturing process;
• patent claims tied to performance data;
• regulatory differentiation from standard tablets.

The most defensible strategy is a layered portfolio covering composition, process, product-by-process, packaging, and use of the formulation in pediatric or adherence-sensitive populations. Method-of-use claims alone are less likely to create durable protection for established indications.

What revenue exposure does tinidazole create?

Tinidazole is unlikely to support large-molecule-style revenue from exclusivity. Revenue depends on volume, geographic reach, product differentiation, and channel access.

The highest-risk commercial model is an undifferentiated 250 mg or 500 mg tablet sold into a crowded generic market. The better opportunity is a product that addresses a specific unmet administration need:

1. pediatric dry suspension;
2. taste-masked granules;
3. single-dose sachet;
4. orally disintegrating or dispersible tablet;
5. institutional unit-dose packaging.

Revenue exposure should be modeled against three scenarios: commodity generic pricing, differentiated formulation pricing, and regional licensing or supply revenue. The main variables are treatment volume, generic substitution, reimbursement, manufacturing cost, stability-related waste, and the number of competitors entering the dosage form.

Key Takeaways

• Tinidazole has no meaningful current U.S. composition-of-matter exclusivity.
• Standard immediate-release tablets face high generic-entry risk.
• Excipient strategy should focus on taste masking, pediatric administration, suspension stability, and dose uniformity.
• Dry powder for reconstitution is more commercially practical than a conventional ready-to-use liquid when stability and logistics are important.
• The strongest patent opportunity is a measurable formulation or manufacturing improvement, not a broad excipient combination.
• A 505(j) pathway is most plausible for a conventional equivalent tablet; novel dosage forms may require a 505(b)(2) strategy.
• Tinidazole is not a biologic and has no biosimilar risk.
• Commercial differentiation is more likely against metronidazole through dosing convenience and pediatric usability than through active-ingredient innovation.
• Licensing value is concentrated in formulation technology, manufacturing capability, and regional commercialization rights.

FAQs

Is tinidazole available as an FDA-approved oral suspension?

The principal U.S. reference product is an immediate-release tablet. A sponsor developing a commercially differentiated suspension would need to address formulation stability, preservative control, dose uniformity, reconstitution or in-use performance, and the applicable FDA regulatory pathway.

Which excipient is best for masking tinidazole taste?

No single excipient is universally optimal. Polymer-coated particles, multiparticulate systems, and lipid-based barriers are more likely to provide durable taste masking than sweeteners and flavors alone. The selected system must preserve gastrointestinal release and bioequivalence.

Can tinidazole be developed as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could target swallowing difficulty and adherence, but the formulation must manage tinidazole’s bitterness, high drug load, mouthfeel, disintegration time, and dissolution profile.

Does tinidazole have biosimilar competition?

No. Tinidazole is a small-molecule antimicrobial, so competition proceeds through generic and hybrid drug pathways rather than the biosimilar framework.

What is the most attractive tinidazole product concept?

A taste-masked pediatric dry suspension or granule product has the strongest excipient-led commercial rationale. It addresses administration barriers that standard tablets do not solve while offering potential formulation, manufacturing, and regulatory differentiation.

References

1. Food and Drug Administration. (2023a). Tindamax (tinidazole) tablets: Prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. National Library of Medicine. (2024). Tinidazole. DailyMed. U.S. National Library of Medicine.

4. World Health Organization. (2023). WHO guidelines for the treatment of sexually transmitted infections. World Health Organization.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984. Pub. L. No. 98-417.